Inflammation-related 5-hydroxymethylation signatures as markers for clinical presentations of coronary artery disease
Authors' conclusion
Our findings suggest that 5hmC modifications in cfDNA reflect CAD-related epigenetic changes and may serve as a promising biomarker for disease stratification. These results provide new insights into the epigenetic landscape of CAD and highlight the potential utility of 5hmC profiling for non-invasive disease monitoring. Further studies are warranted to validate these findings and explore their clinical implications.
Study context
- Population
- Coronary artery disease (CAD) patients stratified into stable CAD (sCAD), non-ST-elevation myocardial infarction (NSTEMI) and ST-elevation myocardial infarction (STEMI); independent external cohortexternal cohort 167
- Participants
- 724 patients
- Comparison
- 19-marker 5hmC-based cell-free DNA (cfDNA) panel for CAD classification
- Outcome
- Classification of CAD disease stages
Methodological detailsmachine learning, internal and external validation
- Machine learning
- Internal and external validation
Performance
As reported in the abstract
| Test or model | AUC, internal validation | AUC, external validation NCA vs sCAD | AUC, external validation sCAD vs MI | AUC, external validation NCA vs MI |
|---|---|---|---|---|
| 5hmC model | 0.913 | 0.784 | 0.880 | 0.918 |
5hmC model
AUC, internal validation0.913
AUC, external validation NCA vs sCAD0.784
AUC, external validation sCAD vs MI0.880
AUC, external validation NCA vs MI0.918
Original publication
Inflammation-related 5-hydroxymethylation signatures as markers for clinical presentations of coronary artery disease. Cardiovasc Diabetol. Published 23 June 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →